AMNEAL PHARMACEUTICALS, INC. (AMRX) Operating Margin
- Operating margin · 12 months: Value 14.56%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 14.56% | Operating income / revenue. Period ending 2026-06-30. $453.92M ÷ $3.12B × 100 ≈ 14.56% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 453.92M USD | Operating Income (Loss) |
| Revenue | 3.12B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.89B USD | Cost of Goods and Services Sold |
| Research and development | 175.57M USD | Research and Development Expense |
| Selling, general and administration | 571.86M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $453.92M | $3.12B | $1.89B | $175.57M | $571.86M | 14.56% |
| 2026-03-31 | $435.52M | $3.05B | $1.87B | $184.52M | $547.40M | 14.30% |
| 2025-12-31 | $394.10M | $3.02B | $1.91B | $186.18M | $526.83M | 13.05% |
| 2025-09-30 | $357.86M | $2.93B | $1.86B | $205.62M | $509.06M | 12.19% |
| 2025-06-30 | $376.32M | $2.85B | $1.78B | $203.37M | $489.93M | 13.19% |
| 2025-03-31 | $360.42M | $2.83B | $1.79B | $191.46M | $482.13M | 12.73% |
| 2024-12-31 | $249.33M | $2.79B | $1.77B | $190.71M | $476.44M | 8.92% |
| 2024-09-30 | $187.73M | $2.68B | $1.73B | $182.53M | $456.75M | 7.00% |
| 2024-06-30 | $174.56M | $2.60B | $1.69B | $162.81M | $451.07M | 6.72% |
| 2024-03-31 | $159.18M | $2.50B | $1.61B | $164.56M | $440.17M | 6.38% |
| 2023-12-31 | $204.37M | $2.39B | $1.57B | $163.95M | $429.68M | 8.54% |
| 2023-09-30 | $226.21M | $2.39B | $1.53B | $159.77M | $422.83M | 9.48% |
| 2023-06-30 | $194.92M | $2.31B | $1.49B | $168.63M | $409.89M | 8.43% |
| 2023-03-31 | $-83.78M | $2.27B | $1.47B | $181.58M | $403.13M | -3.69% |
| 2022-12-31 | $-94.93M | $2.21B | $1.42B | $195.69M | $399.70M | -4.29% |
| 2022-09-30 | $-119.78M | $2.14B | $1.38B | $205.66M | $394.77M | -5.60% |
| 2022-06-30 | $-135.62M | $2.12B | $1.35B | $204.35M | $386.09M | -6.39% |
| 2022-03-31 | $130.11M | $2.10B | $1.32B | $206.46M | $373.44M | 6.20% |
| 2021-12-31 | $152.72M | $2.09B | $1.30B | $201.85M | $365.50M | 7.29% |
| 2021-09-30 | $161.72M | $2.07B | $1.30B | $203.43M | $352.97M | 7.82% |
| 2021-06-30 | $135.64M | $2.06B | $1.32B | $199.03M | $344.69M | 6.59% |
| 2021-03-31 | $79.27M | $1.99B | $1.32B | $191.73M | $339.48M | 3.99% |
| 2020-12-31 | $91.16M | $1.99B | $1.33B | $179.93M | $326.73M | 4.57% |
| 2020-09-30 | $47.84M | $1.88B | $1.26B | $174.52M | $316.12M | 2.55% |
| 2020-06-30 | $-66.87M | $1.74B | $1.17B | $168.13M | $296.80M | -3.85% |
| 2020-03-31 | $-96.53M | $1.68B | $1.15B | $170.57M | $283.14M | -5.75% |
| 2019-12-31 | $-248.68M | $1.63B | $1.15B | $188.05M | $289.60M | -15.29% |
| 2019-09-30 | $-202.27M | $1.73B | $1.19B | $197.30M | $289.34M | -11.71% |
| 2019-06-30 | $-15.44M | $1.82B | $1.19B | $201.52M | $301.03M | -0.85% |
| 2019-03-31 | $-177.59M | $1.83B | $1.13B | $203.84M | $289.75M | -9.68% |
| 2018-12-31 | $-19.67M | $1.66B | $946.59M | $194.19M | $230.44M | -1.18% |
| 2018-09-30 | (m) | $890.27M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $284.88M | $1.02B | $420.77M | $179.02M | $118.76M | 27.98% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |